Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
United Imaging Announces First PET/CT Installation in Mexico, at Instituto Nacional de Pediatría 2024-07-15 20:00
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer 2024-07-15 19:00
Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy 2024-07-15 10:12
Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule 2024-07-12 20:30
Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress 2024-07-12 19:00
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE 2024-07-12 04:00
Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation 2024-07-11 21:00
First Patient Dosed in Phase I Clinical Trial of YOLT-201 2024-07-11 20:11
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC 2024-07-11 20:00
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) 2024-07-11 14:21
ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy' 2024-07-11 14:07
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year 2024-07-10 13:30
Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development 2024-07-08 22:00
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase® 2024-07-08 21:00
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease 2024-07-08 17:23
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME 2024-07-08 17:00
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors 2024-07-08 16:28
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial 2024-07-08 13:41
Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC) 2024-07-05 21:00
IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy 2024-07-05 16:30
1 19 20 21 22 23 431